Jiangsu Sihuan Bioengineering Co Ltd (SHE:000518) — Market Cap & Net Worth
Market Cap & Net Worth: Jiangsu Sihuan Bioengineering Co Ltd (000518)
Jiangsu Sihuan Bioengineering Co Ltd (SHE:000518) has a market capitalization of $465.53 Million (CN¥3.18 Billion) as of April 17, 2026. Listed on the SHE stock exchange, this China-based company holds position #14178 globally and #3931 in its home market, demonstrating a 9.19% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Jiangsu Sihuan Bioengineering Co Ltd's stock price CN¥3.09 by its total outstanding shares 1029556222 (1.03 Billion).
Jiangsu Sihuan Bioengineering Co Ltd Market Cap History: 2015 to 2026
Jiangsu Sihuan Bioengineering Co Ltd's market capitalization history from 2015 to 2026. Data shows change from $1.07 Billion to $465.53 Million (-6.49% CAGR).
Jiangsu Sihuan Bioengineering Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Jiangsu Sihuan Bioengineering Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
1.87x
Jiangsu Sihuan Bioengineering Co Ltd's market cap is 1.87 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $1.07 Billion | $237.84 Million | -$74.45 Million | 4.50x | N/A |
| 2016 | $1.34 Billion | $327.31 Million | $4.47 Million | 4.09x | 299.09x |
| 2017 | $1.03 Billion | $346.05 Million | $7.29 Million | 2.98x | 141.39x |
| 2018 | $521.27 Million | $395.51 Million | -$29.44 Million | 1.32x | N/A |
| 2019 | $546.88 Million | $417.88 Million | $14.33 Million | 1.31x | 38.16x |
| 2020 | $771.36 Million | $505.40 Million | $27.30 Million | 1.53x | 28.26x |
| 2021 | $546.88 Million | $350.96 Million | -$38.27 Million | 1.56x | N/A |
| 2022 | $477.58 Million | $270.15 Million | -$53.28 Million | 1.77x | N/A |
| 2023 | $500.18 Million | $235.42 Million | -$75.27 Million | 2.12x | N/A |
| 2024 | $381.16 Million | $203.52 Million | -$109.99 Million | 1.87x | N/A |
Competitor Companies of 000518 by Market Capitalization
Companies near Jiangsu Sihuan Bioengineering Co Ltd in the global market cap rankings as of April 17, 2026.
Key companies related to Jiangsu Sihuan Bioengineering Co Ltd by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #180 globally with a market cap of $112.07 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #289 globally with a market cap of $78.34 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #369 globally with a market cap of $63.46 Billion USD.
- Alnylam Pharmaceuticals Inc (NASDAQ:ALNY): Ranked #547 globally with a market cap of $44.12 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #180 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $112.07 Billion | $441.70 |
| #289 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $78.34 Billion | $753.93 |
| #369 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #547 | Alnylam Pharmaceuticals Inc | NASDAQ:ALNY | $44.12 Billion | $333.39 |
Jiangsu Sihuan Bioengineering Co Ltd Historical Marketcap From 2015 to 2026
Between 2015 and today, Jiangsu Sihuan Bioengineering Co Ltd's market cap moved from $1.07 Billion to $ 465.53 Million, with a yearly change of -6.49%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥465.53 Million | +28.22% |
| 2025 | CN¥363.08 Million | -4.74% |
| 2024 | CN¥381.16 Million | -23.80% |
| 2023 | CN¥500.18 Million | +4.73% |
| 2022 | CN¥477.58 Million | -12.67% |
| 2021 | CN¥546.88 Million | -29.10% |
| 2020 | CN¥771.36 Million | +41.05% |
| 2019 | CN¥546.88 Million | +4.91% |
| 2018 | CN¥521.27 Million | -49.42% |
| 2017 | CN¥1.03 Billion | -22.97% |
| 2016 | CN¥1.34 Billion | +25.07% |
| 2015 | CN¥1.07 Billion | -- |
End of Day Market Cap According to Different Sources
On Apr 16th, 2026 the market cap of Jiangsu Sihuan Bioengineering Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $465.53 Million USD |
| MoneyControl | $465.53 Million USD |
| MarketWatch | $465.53 Million USD |
| marketcap.company | $465.53 Million USD |
| Reuters | $465.53 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Jiangsu Sihuan Bioengineering Co Ltd
Jiangsu Sihuan Bioengineering Co., Ltd. engages in the pharmaceutical business in China. It offers delusheng and xindelusheng, an anti-tumor biotherapeutic drug for the treatment of kidney cancer, malignant melanoma, and cancerous chest and abdominal mass. It also engages in breeding and sales of flowers and seedlings; and landscaping projects. Jiangsu Sihuan Bioengineering Co., Ltd. was founded … Read more